ACADIA Pharmaceuticals Inc
ACAD22.200USD
-0.370-1.64%
收盤 11/10, 16:00（美東）報價延遲15分鐘
3.76B總市值
14.38本益比TTM
關於 ACADIA Pharmaceuticals Inc 公司
Acadia Pharmaceuticals Inc. 是一家生物製藥公司。該公司專注於開發和商業化藥物，以滿足中樞神經系統 (CNS) 疾病和罕見疾病中未滿足的醫療需求。該公司擁有一系列商業階段產品、開發中產品機會和研究項目，旨在滿足中樞神經系統疾病和罕見疾病中未滿足的需求。其產品線包括 NUPLAZID（匹莫範色林）、DAYBUE（曲芬奈肽）、ACP-101、ACP-204 和反義寡核苷酸 (ASO) 項目。NUPLAZID 是一種選擇性血清素反向激動劑/拮抗劑，優先針對 5-HT2A 受體。NUPLAZID 專爲治療帕金森病精神病而開發。曲芬奈肽是胰島素樣生長因子 1 (IGF-1) 氨基末端三肽的一種新型合成類似物，旨在通過減少神經炎症和支持突觸功能來治療雷特綜合徵的核心症狀。
ACADIA Pharmaceuticals Inc簡介
公司代碼ACAD
公司名稱ACADIA Pharmaceuticals Inc
上市日期May 27, 2004
CEOMs. Catherine Owen Adams
員工數量653
證券類型Ordinary Share
年結日May 27
公司地址12830 El Camino Real
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編92130
電話18585582871
網址https://acadia.com/
公司代碼ACAD
上市日期May 27, 2004
CEOMs. Catherine Owen Adams
ACADIA Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Director
Independent Director
102.88K
--
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Independent Director
Independent Director
24.80K
+60.90%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.10K
-48.90%
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Executive Vice President and Head of Research and Development
Executive Vice President and Head of Research and Development
--
--
Mr. Mark C. Schneyer
Mr. Mark C. Schneyer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Edmund P. Harrigan
Dr. Edmund P. Harrigan
Independent Director
Independent Director
--
--
Mr. Thomas Andrew (Tom) Garner
Mr. Thomas Andrew (Tom) Garner
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Ms. Catherine Owen Adams
Ms. Catherine Owen Adams
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Director
Independent Director
102.88K
--
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Independent Director
Independent Director
24.80K
+60.90%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.10K
-48.90%
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Executive Vice President and Head of Research and Development
Executive Vice President and Head of Research and Development
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q2
FY2023Q1
業務USD
名稱
營收
佔比
NUPLAZID
168.48M
63.68%
DAYBUE
96.09M
36.32%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
NUPLAZID
168.48M
63.68%
DAYBUE
96.09M
36.32%
股東統計
更新時間: 10月8日 週三
更新時間: 10月8日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Baker Bros. Advisors LP
25.36%
BlackRock Institutional Trust Company, N.A.
10.77%
The Vanguard Group, Inc.
8.96%
RTW Investments L.P.
5.32%
State Street Investment Management (US)
3.65%
其他
45.95%
持股股東
持股股東
佔比
Baker Bros. Advisors LP
25.36%
BlackRock Institutional Trust Company, N.A.
10.77%
The Vanguard Group, Inc.
8.96%
RTW Investments L.P.
5.32%
State Street Investment Management (US)
3.65%
其他
45.95%
股東類型
持股股東
佔比
Hedge Fund
36.76%
Investment Advisor
34.34%
Investment Advisor/Hedge Fund
25.10%
Research Firm
3.90%
Pension Fund
1.27%
Sovereign Wealth Fund
0.91%
Individual Investor
0.56%
Bank and Trust
0.34%
Venture Capital
0.06%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
670
173.25M
102.40%
-15.51M
2025Q2
671
174.83M
104.44%
-12.86M
2025Q1
688
177.74M
106.20%
-7.86M
2024Q4
643
167.35M
100.34%
-11.57M
2024Q3
599
161.17M
97.17%
-22.69M
2024Q2
603
166.04M
100.49%
-20.26M
2024Q1
612
167.37M
101.58%
-15.73M
2023Q4
589
164.89M
100.43%
-16.10M
2023Q3
560
161.37M
98.56%
-19.17M
2023Q2
557
164.35M
101.06%
-15.99M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Baker Bros. Advisors LP
42.90M
25.43%
+18.77K
+0.04%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
18.22M
10.8%
-552.34K
-2.94%
Jun 30, 2025
The Vanguard Group, Inc.
15.24M
9.03%
+61.01K
+0.40%
Jun 30, 2025
RTW Investments L.P.
9.00M
5.33%
+455.43K
+5.33%
Jun 30, 2025
State Street Investment Management (US)
6.18M
3.66%
-815.47K
-11.66%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.19M
1.89%
-1.07M
-25.06%
Jun 30, 2025
Point72 Asset Management, L.P.
3.17M
1.88%
-1.48M
-31.74%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.02M
1.79%
+69.58K
+2.36%
Jun 30, 2025
Citadel Advisors LLC
3.01M
1.79%
+2.72M
+922.43%
Jun 30, 2025
Palo Alto Investors LP
2.56M
1.52%
-100.72K
-3.78%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Alger Weatherbie Enduring Growth ETF
3.79%
iShares Neuroscience and Healthcare ETF
3.51%
First Trust NYSE Arca Biotechnology Index Fund
3.16%
Invesco Biotechnology & Genome ETF
2.22%
ALPS Medical Breakthroughs ETF
2.12%
Invesco S&P SmallCap Health Care ETF
1.69%
Virtus LifeSci Biotech Products ETF
1.63%
Invesco S&P SmallCap 600 GARP ETF
1.14%
SPDR S&P Biotech ETF
1.07%
Invesco S&P SmallCap Quality ETF
0.67%
查看更多
Alger Weatherbie Enduring Growth ETF
佔比3.79%
iShares Neuroscience and Healthcare ETF
佔比3.51%
First Trust NYSE Arca Biotechnology Index Fund
佔比3.16%
Invesco Biotechnology & Genome ETF
佔比2.22%
ALPS Medical Breakthroughs ETF
佔比2.12%
Invesco S&P SmallCap Health Care ETF
佔比1.69%
Virtus LifeSci Biotech Products ETF
佔比1.63%
Invesco S&P SmallCap 600 GARP ETF
佔比1.14%
SPDR S&P Biotech ETF
佔比1.07%
Invesco S&P SmallCap Quality ETF
佔比0.67%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
